A genetically encoded fluorescent sensor enables sensitive and specific detection of IDH mutant associated oncometabolite D-2-hydroxyglutarate.

A recent preprint abstract discusses the development of a genetically encoded fluorescent sensor called D2HGlo, which can detect the oncometabolite D-2-hydroxyglutarate (D-2-HG). D-2-HG is associated with mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) and can be used as a marker for IDH1/2 mutant cancers. D2HGlo has shown exceptional selectivity and can accurately quantify D-2-HG in various body fluids and glioma tumor supernatants. The sensor has the potential to be used as an in vitro diagnostic device for the detection and monitoring of IDH mutant cancers through liquid biopsies. The study also presents preliminary findings on the adaptation of D2HGlo to the cellular environment, specifically in immortalized glioma cells. However, it is important to note that this preprint has not yet undergone peer review. [Extracted from the article]